ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

计划入组 148 人 · 首次发布于 2023 年 1 月 12 日

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

计划入组 1,524 人 · 首次发布于 2025 年 10 月 1 日

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

计划入组 20 人 · 首次发布于 2026 年 7 月 6 日

Lutetium Lu-177 vipivotide tetraxetan(Pluvicto)

C₄₉H₆₈LuN₉O₁₆

177Lu-EB-PSMA-617

vipivotide tetraxetan

Laureate Institute for Brain Research

United States

Aveta Biomics, Inc.

United States

Selcuk University

Turkey

Lutetium Lu 177 Vipivotide Tetraxetan Shows Promise in Prostate Cancer Treatment

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Advances in Metastatic Prostate Cancer Treatment: Avenues for Extending Survival